Charles Schwab’s Protalix BioTherapeutics PLX Stock Holding History

Charles Schwab’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$420K	Buy	180,381 +21,070	+13%	+$44.6K	﹤0.01%	3269
2026 Q1	$346K	Sell	159,311 -15,759	-9%	-$39.1K	﹤0.01%	3211
2025 Q4	$315K	Hold	175,070	–	–	﹤0.01%	3268
2025 Q3	$389K	Hold	175,070	–	–	﹤0.01%	3238
2025 Q2	$259K	Buy	+175,070	New	+$358K	﹤0.01%	3345
2024 Q2	–	Sell	-153,561	Closed	-$193K	–	3667
2024 Q1	$193K	Hold	153,561	–	–	﹤0.01%	3243
2023 Q4	$273K	Hold	153,561	–	–	﹤0.01%	3232
2023 Q3	$255K	Buy	153,561 +25,143	+20%	+$45.1K	﹤0.01%	3243
2023 Q2	$257K	Buy	+128,418	New	+$306K	﹤0.01%	3267

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Charles Schwab's PLX Position: Q2 2026 in Review

Charles Schwab increased its Protalix BioTherapeutics (PLX) stake by 13% in Q2 2026, buying an estimated $44.6K and bringing the position to 180,381 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #3269.

Charles Schwab first reported a position in PLX in Q2 2023 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Charles Schwab held 180,381 shares of Protalix BioTherapeutics worth $420K as of Q2 2026.
Charles Schwab bought 21,070 Protalix BioTherapeutics shares in Q2 2026, an estimated $44.6K.
Protalix BioTherapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3269 holding.
Charles Schwab first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 9 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.